Epitope analysis of a prostate-specific antigen (PSA) C-Terminal- specific monoclonal antibody and new aspects for the discrepancy between equimolar and skewed PSA assays

Clinical Chemistry

Volumn 45, Issue 4, 1999, Pages 486-496

  Nagasaki, Hiroshi ^a   Watanabe, Motoyuki ^a   Komatsu, Naoki ^a   Kaneko, Takashi ^a   Dubé, Jean Y ^b   Kajita, Tadahiro ^c   Saitoh, Yoshihiro ^c   Ohta, Yohsuke ^c  

^a New Products and Technology Laboratory   (Japan)

^b UNIVERSITÉ LAVAL   (Canada)

^c International Reagents Corporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ANTIBODY AFFINITY; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CROSS REACTION; EPITOPE MAPPING; IMMUNOASSAY; INTERMETHOD COMPARISON; PROTEIN INTERACTION; QUANTITATIVE ASSAY; SEQUENCE HOMOLOGY; WESTERN BLOTTING;

EID: 0032917738     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.4.486     Document Type: Article

References (42)

1. 1. Clements JA. The human kallikrein gene family: a diversity of expression and function. Mol Cell Endocrinol 1994;99:C1-6.
2. 2. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM. Prostate antigen: a new potential marker for prostate cancer. Prostate 1981;2:89-96.
3. 3. Lilja H, Abrahamsson PA. Three predominant proteins secreted by the human prostate gland. Prostate 1988;12:29-38.
4. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51: 222-6.
5. 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
6. 1-antichymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones. J Urol 1994;152:1510-4.
7. 7. Armbruster DA. Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem 1993;39:181-95.
8. 8. Chan DM, Bruzek DJ, Oesterling JE, Rock RC, Walsh PC. Prostate-specific antigen as a marker for prostate cancer: a monoclonal and a polyclonal immunoassay compared. Clin Chem 1987;33: 1916-20.
9. 9. Horton GL, Bahnson RR, Daft M, Chan KM, Catalona WJ, Ladenson JH. Differences in values obtained with two assays of prostate specific antigen. J Urol 1988;139:762-72.
10. 10. Graves HCB, Wehner N, Stamey TA. Comparison of a polyclonal and monoclonal immunoassay for PSA: need for an international specific antigen standard. J Urol 1990;144:1516-22.
11. 11. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 1993;39:2483-91.
12. 12. Wians FH Jr. The correct PSA concentration [Letter]. Clin Chem 1996;42:1882-4.
13. 13. Blase AB, Sokoloff RL, Smith KM. Five PSA methods compared by assaying samples with defined PSA ratios [Letter]. Clin Chem 1997;43:843-5.
14. 14. Vessella RL, Noteboom J, Lange PH. Evaluation of Abbott IMx automated immunoassay of prostate-specific antigen. Clin Chem 1992;38:2044-54.
15. 15. Stamey TA. Second Stanford conference on international standardization of prostate-specific antigen immunoassays: September 1 and 2, 1994. Urology 1995;45:173-84.
16. 16. Smith RD, Loo JA, Edmonds CG, Barinaga CJ, Udeth HR. New developments in biochemical mass spectrometry: electrospray ionization. Anal Chem 1990;62:882-99.
17. 17. Johnsson B, Löfás S, Lindquvist G. Immobilization of proteins to a carboxymethyl dextran modified gold surface for biospecific interaction analysis in surface plasmon resonance. Anal Biochem 1991;198:268-77.
18. 18. Fägerstam L. A non-label technology for real time biospecific interaction analysis. Tech Protein Chem 1991;2:265-71.
19. 19. Schedlich LJ, Bennetts BH, Morris BJ. Primary structure of human glandular kallikrein gene. DNA 1987;6:429-37.
20. 20. Deperthes D, Chapdelaine P, Tremblay RR, Brunet C, Berton J, Hébert J, et al. Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma. Biochim Biophys Acta 1995; 1245:311-6.
21. 21. Oesterling JE, Jacobson SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154: 1090-5.
22. 22. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
23. 23. Wang TJ, Hill TM, Sokoloff RL, Frankenne F, Rittenhouse HG, Wolfert RL. Dual monoclonal antibody immunoassay for free prostate-specific antigen. Prostate 1996;28: 10-6.
24. 24. Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part 1. Results of a retrospective evaluation of 1726 men. Urology 1995;46:773-8.
25. 25. Cangh PJ, De Nayer P, Sauvage P, Tombal B, Elsen M, Lorge F, et al. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate Suppl 1996;7:30-4.
26. 26. Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate Suppl 1996;7:3-16.
27. 27. Demura T, Watari Y, Togashi M, Hirano T, Ohashi N, Koyanagi T. Measurement of prostate specific antigen and γ-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer. J Urol 1993;150:1740-5.
28. 1-antichymotrypsin. Potential reference material for international standardization of PSA immunoassays. Clin Chem 1995;41:1273-82.
29. 29. Stamey TA, Teplow DB, Graves HCB. Identification of PSA purified from seminal fluid by different methods: comparison by amino acid analysis and assigned extinction coefficients. Prostate 1995; 27:198-203.
30. 30. Hsia CY, Ganshaw G, Paech C, Murray CC. Active-site titration of serine proteases using a fluoride ion selective electrode and sulfonyl fluoride inhibitors. Anal Chem 1996;242:221-7.
31. 31. Bélanger A, van Halbeek H, Graves HCB, Grandbois K, Stamey TA, Huang L, et al. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate 1995;27:187-97.
32. 32. Siddall JK, Shetty SD, Cooper EH. Measurements of γ-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of prostate. Clin Chem 1986;32:2040-3.
33. 33. Kuriyama M, Takeuchi T, Shinoda I, Okano M, Nishiura T. Clinical evaluation of γ-seminoprotein in prostate cancer. Prostate 1986; 8:301-11.
34. 34. Schaller J, Akiyama K, Tsuda R, Hara M, Marti T, Rickli EE. Isolation and characterization of γ-seminoprotein, a glycoprotein from human seminal plasma. Eur J Biochem 1987;170:111-20.
35. 35. Nilsson O, Peter A, Andersson I, Nilsson K, Grundström B, Karlsson B. Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA. Br J Cancer 1997;75:789-97.
36. 36. Bridon D, Lowell B. Structure comparison of prostate-specific antigen and human glandular kallikrein. Urology 1995;45:801-6.
37. 37. Gaboriaud C, Serre L, Guy-Crotte O, Forest, E, Fontecilla-Camps J-C. Crystal structure of human trypsin 1: unexpected phosphorylation of Tyr151. J Mol Biol 1996;259:995-1010.
38. 38. Doyle DA, Lee A, Lewis J, Kim E, Sheng M, MacKinnon R. Crystal structures of a complexed and peptide-free membrane protein-binding domain: Molecular basis of peptide recognition by PDZ. Cell 1996;85:1067-76.
39. 39. Songyang Z, Fanning AS, Fu C, Xu J, Marfatia SM, Chishti AH, et al. Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science 1997;275:73-7.
40. 1-antichymotrypsin complex. Clin Chem 1995;41: 1480-8.
41. 41. Yu H, Diamandis EP, Sutherland DJA. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994;27:75-9.
42. 42. Diamandis EP, Yu H, Sutherland DJA. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 1994;32:301-10.